- Home
- DUO vs BCLI Comparison
DUO vs BCLI Comparison
Compare DUO & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- BCLI
- Stock Information
- Founded
- DUO 2011
- BCLI 2000
- Country
- DUO China
- BCLI United States
- Employees
- DUO N/A
- BCLI N/A
- Industry
- DUO Real Estate
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DUO Finance
- BCLI Health Care
- Exchange
- DUO Nasdaq
- BCLI Nasdaq
- Market Cap
- DUO 11.4M
- BCLI 9.8M
- IPO Year
- DUO 2019
- BCLI N/A
- Fundamental
- Price
- DUO $2.32
- BCLI $1.16
- Analyst Decision
- DUO
- BCLI Strong Buy
- Analyst Count
- DUO 0
- BCLI 1
- Target Price
- DUO N/A
- BCLI $30.00
- AVG Volume (30 Days)
- DUO 174.4K
- BCLI 409.2K
- Earning Date
- DUO 08-29-2025
- BCLI 08-13-2025
- Dividend Yield
- DUO N/A
- BCLI N/A
- EPS Growth
- DUO N/A
- BCLI N/A
- EPS
- DUO 7.57
- BCLI N/A
- Revenue
- DUO $46,458,330.00
- BCLI N/A
- Revenue This Year
- DUO N/A
- BCLI N/A
- Revenue Next Year
- DUO N/A
- BCLI N/A
- P/E Ratio
- DUO $0.30
- BCLI N/A
- Revenue Growth
- DUO 19.00
- BCLI N/A
- 52 Week Low
- DUO $1.97
- BCLI $0.72
- 52 Week High
- DUO $74.72
- BCLI $6.45
- Technical
- Relative Strength Index (RSI)
- DUO 37.94
- BCLI 49.98
- Support Level
- DUO $1.97
- BCLI $1.02
- Resistance Level
- DUO $2.49
- BCLI $1.32
- Average True Range (ATR)
- DUO 0.17
- BCLI 0.09
- MACD
- DUO 0.02
- BCLI -0.00
- Stochastic Oscillator
- DUO 45.86
- BCLI 46.67
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.